Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.61 |
| ▸ | HINT1 | P49773 | 3/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ADK | P55263 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9791204 | 1.00 | ADORA3 (0.61) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL27375734 | 1.00 | ADORA3 (0.61) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL4527412 | 1.00 | ADORA3 (0.61) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL4278130 | 0.86 | HINT1 (0.62) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL2510562 | 0.86 | HINT1 (0.62) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL24299397 | 0.86 | HINT1 (0.62) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL19938159 | 0.86 | HINT1 (0.62) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL13833323 | 0.86 | HINT1 (0.62) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL16114092 | 0.86 | HINT1 (0.62) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL5360770 | 0.85 | HINT1 (0.56) | ADORA3HINT1NT5ECYP2C19ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488598-B2 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | CORNELL CENTER FOR TECHNOLOGY ENTERPRISE AND COMMERCIALIZATION (US) | 2009-02-10 | — | — | US | disclosed |
| EP-1444335-A4 | MUTANT PURINE NUCLEOSIDE PHOSPHORYLASE PROTEINS AND CELLULAR DELIVERY THEREOF | UAB RESEARCH FOUNDATION (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050214901-A1 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | CORNELL CENTER FOR TECHNOLOGY, ENTERPRISE & COIMMERCIALIZATION | 2005-09-29 | — | — | US | disclosed |
| EP-1444335-A2 | MUTANT PURINE NUCLEOSIDE PHOSPHORYLASE PROTEINS AND CELLULAR DELIVERY THEREOF | UAB Research Foundation (US) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003035012-A2 | MUTANT PURINE NUCLEOSIDE PHOSPHORYLASE PROTEINS AND CELLULAR DELIVERY THEREOF | UAB RESEARCH FOUNDATION (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050214901-A1 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | PNP, UPP1, TYMP | ADORA3 974/4885HINT1 127/4885NT5E 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.